3D Systems Solidifies Additive Manufacturing Focus with Strategic Simbionix Divestment

In a monumental move underscoring its unwavering commitment to additive manufacturing, 3D Systems has officially announced the sale of its medical simulation business, Simbionix. This significant transaction, valued at $305 million USD, sees Simbionix acquired by Surgical Science Sweden AB, a globally recognized leader in providing virtual reality simulators for advanced medical training. This divestment marks the successful completion of a comprehensive strategic initiative launched earlier this year by 3D Systems, meticulously designed to streamline its operations and sharpen its focus on propelling growth and expanding margins within the dynamic and rapidly evolving additive manufacturing (AM) sector. This strategic pivot reinforces 3D Systems’ dedication to its core strengths and positions it to capitalize fully on the immense opportunities within industrial 3D printing.

This recent sale is a critical step in a broader strategy that began to unfold last month when 3D Systems also divested its on-demand manufacturing service for a substantial $82 million USD. Over the past year, the company has consistently communicated its renewed vision to investors and clients alike: an intensive focus on additive manufacturing, consolidating its resources and expertise around this pivotal core business. Beyond these strategic divestitures of non-AM assets, such as the medical simulation and on-demand businesses, 3D Systems has simultaneously reinforced its AM capabilities through targeted investments. Earlier this year, the company acquired Allevi, Inc., significantly bolstering its bioprinting portfolio, and also brought Additive Works into its fold, enhancing its software offerings crucial for optimizing advanced 3D printing workflows. Furthermore, to accommodate the escalating customer demand for cutting-edge AM technologies, 3D Systems has unveiled plans for substantial expansions of its facilities in both Rock Hill, South Carolina, and Littleton, Colorado, signaling robust future growth.

A Strategic Pivot Towards Additive Manufacturing Excellence

This series of strategic transactions represents a clear and decisive shift for 3D Systems, an industry pioneer with a rich history in 3D printing. By divesting assets that do not directly align with its core additive manufacturing mission, the company aims to allocate resources more efficiently towards innovation, research and development, and market penetration within the AM space. The global additive manufacturing market continues to expand rapidly, driven by technological advancements, increasing adoption across diverse industries like healthcare, aerospace, and automotive, and a growing demand for customized, high-performance parts. This strategic focus enables 3D Systems to dedicate its engineering prowess and business development efforts entirely to pioneering new materials, improving printer performance, and developing advanced software solutions that optimize the entire AM workflow, from design to post-processing.

The acquisition of Allevi, Inc. earlier this year exemplifies this commitment to innovation, particularly in the burgeoning field of bioprinting. Bioprinting, a revolutionary application of 3D printing, involves fabricating biological structures layer by layer, often using living cells and biomaterials. This technology holds immense promise for tissue engineering, regenerative medicine, and drug discovery, potentially leading to the creation of organs for transplant and advanced pharmaceutical testing models. Similarly, the integration of Additive Works strengthens 3D Systems’ software capabilities, offering sophisticated tools for simulation, design optimization, and process management, which are critical for achieving consistent quality and efficiency in complex additive manufacturing applications. These targeted investments are not just about adding new technologies; they are about creating a comprehensive, synergistic ecosystem that supports end-to-end additive manufacturing solutions for industrial customers.

The planned facility expansions in Rock Hill, South Carolina, and Littleton, Colorado, are a direct response to the escalating demand for 3D Systems’ innovative technologies. These expansions will not only increase manufacturing capacity but also foster an environment for enhanced research and development, allowing the company to accelerate the introduction of next-generation 3D printers, materials, and software. This proactive approach ensures that 3D Systems remains at the forefront of additive manufacturing, capable of meeting the evolving needs of its global customer base and sustaining its leadership position in a competitive market.

Leadership Perspective on Divestment

Commenting on these transformative changes to 3D Systems’ larger business infrastructure, Dr. Jeffrey Graves, the President and CEO of the company, articulated the strategic rationale with clarity. He stated, “Over the last several months, 3D Systems has divested a number of assets that are not core to our industry-leading additive manufacturing solutions business.” Dr. Graves further elaborated, emphasizing the finality of this strategic phase: “The final of these is our Simbionix business, under the leadership of Ran Bronstein, which has secured a strong position in the medical simulation, training and robotic surgery market. As the Simbionix team now joins forces with Surgical Science, I believe their future will be even brighter, with increased scale and an ability to leverage the core strengths of both businesses in a growing medical simulation market.” His statements underscore a vision of deliberate strategic focus, aiming to maximize shareholder value and market impact by concentrating on areas where 3D Systems holds a distinct competitive advantage.

Simbionix: A New Chapter with Surgical Science

The divestment of Simbionix to Surgical Science Sweden AB is not merely a transaction for 3D Systems; it also represents a significant growth opportunity for Simbionix itself. Simbionix has long been recognized for its pioneering work in medical simulation, offering state-of-the-art virtual reality platforms that enable surgeons and medical professionals to practice complex procedures in a risk-free environment. This includes simulations for laparoscopic surgery, endoscopy, catheterization, and increasingly, advanced robotic surgery. Under the leadership of Ran Bronstein, Simbionix has established itself as a critical partner in medical education and training, contributing significantly to patient safety and surgical proficiency worldwide. The integration with Surgical Science, another powerhouse in medical simulation, promises to create a formidable market leader, combining their respective strengths in technology, market reach, and innovation to drive forward the next generation of medical training tools.

Strengthening Financial Position for Future Growth

With the successful completion of the Simbionix sale, 3D Systems has concluded its comprehensive initiative to divest non-additive manufacturing related businesses. This strategic cleansing allows the company to fully concentrate its considerable resources and intellectual capital on its core AM solutions and applications. A pivotal outcome of this transaction is 3D Systems’ projected financial transformation: the company not only expects to be entirely debt-free but will also command a robust cash balance of approximately $500 million USD post-transaction. This exceptional financial strength provides 3D Systems with unparalleled flexibility and capacity to accelerate its investments in cutting-edge research and development, pursue strategic acquisitions within the AM ecosystem, and expand its global market presence. It ensures the company is well-capitalized to innovate and execute on its long-term vision without the burden of significant debt.

Furthermore, 3D Systems actively emphasizes the mutual benefits of this strategic realignment, particularly highlighting the positive outlook for Simbionix. According to the official press release, the integration of Simbionix into Surgical Science is poised to form a true market-leading entity in the rapidly evolving fields of medical procedure simulation and advanced robotic surgery. This synergy is expected to enhance both companies’ abilities to innovate, develop new products, and expand their global footprint in critical medical training. The completion of this landmark transaction is anticipated to occur in August 2021, marking a new chapter for both organizations. For more detailed insights, stakeholders and interested parties are encouraged to review the comprehensive press release from 3D Systems available HERE.

3D Systems’ Vision for the Future of AM

This decisive move firmly establishes 3D Systems as a pure-play additive manufacturing company, dedicated to pushing the boundaries of what’s possible with 3D printing technologies. Their strategic focus encompasses a wide array of AM solutions, including stereolithography (SLA), selective laser sintering (SLS), direct metal printing (DMP), and the aforementioned bioprinting. By concentrating on these core areas, 3D Systems can accelerate the development of groundbreaking applications in critical sectors such as personalized healthcare, high-performance aerospace components, advanced automotive manufacturing, and precision industrial tooling. The company’s enhanced financial position, coupled with its streamlined operational structure, empowers it to invest more heavily in material science, software intelligence, and hardware innovation, ensuring it delivers unparalleled solutions to its industrial customers globally.

The strategic clarity achieved through these divestitures is expected to significantly benefit 3D Systems’ customers by fostering a more specialized and responsive product development cycle. With a singular focus on additive manufacturing, the company can channel all its expertise into delivering improved product quality, more efficient workflows, and enhanced customer support tailored specifically to the AM ecosystem. This sharpened focus not only reinforces 3D Systems’ leadership position in the additive manufacturing industry but also underscores its long-term vision to be the essential partner for businesses seeking to leverage the transformative power of 3D printing for innovation and competitive advantage.

What are your thoughts on 3D Systems’ strategic sale of Simbionix and their intensified focus on additive manufacturing? We invite you to share your perspectives in the comments section below or join the conversation on our Facebook and Twitter pages. Don’t miss out on the latest advancements and news in the world of 3D printing – remember to sign up for our free weekly newsletter, delivered directly to your inbox!